BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24612787)

  • 1. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
    Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
    J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
    Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
    Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
    Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
    Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
    Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
    Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
    Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
    Iinuma H; Fukushima R; Inaba T; Tamura J; Inoue T; Ogawa E; Horikawa M; Ikeda Y; Matsutani N; Takeda K; Yoshida K; Tsunoda T; Ikeda T; Nakamura Y; Okinaga K
    J Transl Med; 2014 Apr; 12():84. PubMed ID: 24708624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
    Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M
    J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
    Inoue K; Sugiura F; Kogita A; Yoshioka Y; Sukegawa Y; Hida J; Okuno K
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1276-9. PubMed ID: 25335716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
    Sugiura F; Inoue K; Okuno K; Sukegawa Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
    Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
    Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    J Transl Med; 2014 Mar; 12():61. PubMed ID: 24606884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
    Kono K; Mizukami Y; Daigo Y; Takano A; Masuda K; Yoshida K; Tsunoda T; Kawaguchi Y; Nakamura Y; Fujii H
    Cancer Sci; 2009 Aug; 100(8):1502-9. PubMed ID: 19459850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
    Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
    Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.
    Higashihara Y; Kato J; Nagahara A; Izumi K; Konishi M; Kodani T; Serizawa N; Osada T; Watanabe S
    Int J Oncol; 2014 Mar; 44(3):662-8. PubMed ID: 24398900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
    Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS
    J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
    Okuno K; Sugiura F; Hida J; Tokoro T; Ishimaru E; Ueda K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1906-8. PubMed ID: 22202234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
    Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.